AI assistant
LUMIBIRD — Earnings Release 2020
Jan 25, 2021
1490_iss_2021-01-25_36ecb579-4984-4339-a358-c98d32433688.pdf
Earnings Release
Open in viewerOpens in your device viewer
Lannion, January 25, 2021 5:45pm
2020 FULL-YEAR REVENUES IN LINE WITH EXPECTATIONS AT -FOR-LIKE (-9.7% YOY AND +2.1% IN Q4)
The LUMIBIRD Group, the European leader for laser technologies, is reporting full- (+2.1%) and
In the crisis context that affected 2020, full-year organic growth is down -9.7% or approximately - MegaJoule contract (- s 1 and the drop in sales linked to the cancellation of major global shows (-
With better visibility concerning its markets and after further strengthening its financial, industrial and commercial capabilities, LUMIBIRD plans to continue moving forward with its organic and external growth strategy to double its revenues (reported basis) by 2023, with average organic annual growth of 8% to 10% and a target EBITDA margin of 20% to 25%.
| Revenues ( ) |
2020 | 2019 | Reported change |
Organic change 1 |
pro forma 2020 2 |
|---|---|---|---|---|---|
| First quarter | 21.9 | 24.2 | -9.5% | -16.7% | |
| Second quarter | 23.9 | 27.5 | -13.3% | -17.2% | |
| Third quarter | 32.7 | 24.8 | +32.1% | -9.9% | |
| Fourth quarter | 48.2 | 34.2 | +40.7% | +2.1% | |
| 12 months | 126.7 | 110.7 | +14.4% | -9.7% | 146.4 |
| of which | |||||
| Photonic (formerly Laser) | 68.5 | 71.4 | -4.1% | -10.6% | 68.5 |
| Medical | 58.2 | 39.3 | +48.1% | -8.0% | 77.9 |
Consolidated revenues (unaudited)
1 Organic change: at constant exchange rates and like-for-like
2 Including Ellex at January 1, 2020
- Like-for-like and at constant exchange rates (restated for the acquisitions of Ellex at June 30, 2020,
1 Previously the "Laser" division
the Essmed Group at July 31, 2020, Optotek Medical at August 31, 2019 and Halo Photonics at December 24, 2019), they are down activities at January 1, pro-
The Group is reporting record fourththe backdrop of the health and economic crisis. Like-for-like and at constant exchange rates, the Medical division came in stable for the last quarter (-0.5%), while the Photonics division achieved 3.7% growth.
With a more detailed analysis, the Industrial and Scientific business continued to be penalized by the closure of many universities and research laboratories, with a 4.4% contraction for the quarter. The Defense / Space business returned to growth (+3.8%), reflecting the combined impact of the planned scaling down of the MegaJoule contract that began in the fourth quarter of 2019 and the ramping up of both new contracts and the non-contracts business. The Lidar Sensors business benefited , as well as 14.7% organic growth for the last quarter.
Despite the restrictions introduced with the health crisis, the integration of Ellex and the development of commercial and industrial synergies have moved forward as planned, with sales for the new combined structure in line with the budget set, including operations in the United States.
LUMIBIRD is approaching 2021 with confidence, backed by an extensive order book, confirming the
Looking ahead to 2023, the Group plans to continue moving forward with its combined organic and external growth strategy with a view to doubling its current revenues (reported basis). Building on its buoyant markets, its capacity for innovation and the impact of its commercial synergies, it is targeting 8% to 10% average organic growth over the next three years.
In terms of profitability, looking beyond the expected synergies, performance on purchases, supply chain rationalization and growing vertical integration are expected to contribute towards the target for EBITDA margin growth of 20% to 25% from 2021.
Next date:
2020 full-year earnings on March 16, 2021 after close of trading
LUMIBIRD is one of the world's leading specialists in lasers. With 50 years of experience and a mastering of solid state laser, laser diodes and fiber laser technologies, the Group designs, manufactures and markets high performance lasers for scientific (laboratories and universities), industrial (manufacturing, defense, Lidar sensors) and medical (ophthalmology) markets.
Born from the combination of Keopsys Group with Quantel in October 2017, LUMIBIRD has more than 800 employees and 26 million of consolidated revenues in 2020 and is present in Europe, America and Asia.
LUMIBIRD shares are listed on the Euronext Paris B Compartment. FR0000038242 LBIRD www.lumibird.com
Contacts
LUMIBIRD Marc Le Flohic Chairman and CEO Tel. +33(0) 1 69 29 17 00 [email protected]
LUMIBIRD Aude Nomblot-Gourhand Secretary General CFO Tel. +33(0) 1 69 29 17 00 [email protected]
Calyptus Mathieu Calleux Investors Relations Tel. +33(1) 53 65 37 91 [email protected]